Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-06-12 4:30 pm Purchase | 2023-05-31 | 13G | TScan Therapeutics, Inc. TCRX | ADAGE CAPITAL PARTNERS GP L.L.C. | 4,000,000 9.350% | 4,000,000 (New Position) | Filing History |
| 2023-06-08 1:25 pm Sale | 2023-05-31 | 13G | TScan Therapeutics, Inc. TCRX | BlackRock Inc. BLK | 1,267,188 3.000% | -246,758 (-16.30%) | Filing History |
| 2023-06-05 4:45 pm Purchase | 2023-05-26 | 13G | TScan Therapeutics, Inc. TCRX | BIOTECHNOLOGY VALUE FUND L P | 4,414,910 9.990% | 4,414,910 (New Position) | Filing History |
| 2023-06-05 4:09 pm Purchase | 2023-05-26 | 13G | TScan Therapeutics, Inc. TCRX | EcoR1 Capital, LLC | 5,000,000 11.700% | 5,000,000 (New Position) | Filing History |
| 2023-06-02 4:56 pm Purchase | 2023-05-31 | 13G | TScan Therapeutics, Inc. TCRX | Lynx1 Capital Management LP | 5,224,600 12.200% | 5,224,600 (New Position) | Filing History |
| 2023-06-02 4:06 pm Purchase | 2023-05-25 | 13D | TScan Therapeutics, Inc. TCRX | Baker Bros. Advisors LP | 2,793,938 6.500% | 9,146 (+0.33%) | Filing History |
| 2023-02-14 4:11 pm Sale | 2022-12-31 | 13G | TScan Therapeutics, Inc. TCRX | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 0 0.000% | -1,282,976 (Position Closed) | Filing History |
| 2023-02-03 4:27 pm Purchase | 2022-12-31 | 13G | TScan Therapeutics, Inc. TCRX | BlackRock Inc. BLK | 1,513,946 8.000% | 15,408 (+1.03%) | Filing History |
| 2022-09-30 5:21 pm Purchase | 2022-09-09 | 13G | TScan Therapeutics, Inc. TCRX | K2 HealthVentures Equity Trust LLC | 2,099,809 9.985% | 2,099,809 (New Position) | Filing History |
| 2022-08-15 5:10 pm Sale | 2022-08-15 | 13G | TScan Therapeutics, Inc. TCRX | RA Capital Management, L.P. | 0 0.000% | -1,255,317 (Position Closed) | Filing History |
| 2022-05-12 4:45 pm Purchase | 2022-05-10 | 13D | TScan Therapeutics, Inc. TCRX | Baker Bros. Advisors LP | 2,784,792 14.700% | 1,359,792 (+95.42%) | Filing History |
| 2022-02-14 5:24 pm Purchase | 2021-12-31 | 13G | TScan Therapeutics, Inc. TCRX | Deer IX & Co. Ltd. | 1,245,505 6.700% | 1,245,505 (New Position) | Filing History |
| 2022-02-14 4:03 pm Purchase | 2021-12-31 | 13G | TScan Therapeutics, Inc. TCRX | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 1,282,976 6.900% | 1,282,976 (New Position) | Filing History |
| 2022-02-14 11:39 am Purchase | 2021-12-31 | 13G | TScan Therapeutics, Inc. TCRX | GV 2017 L.P. | 1,077,080 5.780% | 1,077,080 (New Position) | Filing History |
| 2022-02-14 09:38 am Purchase | 2021-12-31 | 13G | TScan Therapeutics, Inc. TCRX | Pitango HealthTech Fund I L.P. | 1,079,985 4.600% | 1,079,985 (New Position) | Filing History |
| 2022-02-10 5:25 pm Purchase | 2021-12-31 | 13G | TScan Therapeutics, Inc. TCRX | Longwood Fund IV L.P. | 2,315,423 12.400% | 2,315,423 (New Position) | Filing History |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | TScan Therapeutics, Inc. TCRX | BlackRock Inc. BLK | 1,498,538 8.000% | 1,498,538 (New Position) | Filing History |
| 2021-07-28 4:30 pm Purchase | 2021-07-20 | 13G | TScan Therapeutics, Inc. TCRX | RA Capital Management, L.P. | 1,255,317 6.700% | 1,255,317 (New Position) | Filing History |
| 2021-07-22 4:20 pm Purchase | 2021-07-20 | 13D | TScan Therapeutics, Inc. TCRX | Baker Bros. Advisors LP | 1,425,000 7.600% | 1,425,000 (New Position) | Filing History |